Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade

Bibliographic Details
Main Authors:	Jeong Hun Kim, Won Suk Lee, Seung Joon Lee, Hannah Yang, Hong Jae Chon, Chan Kim, Jin Hyoung Kim, Byung cheol Ahn, Dong Sung Kim, Yoonki Heo, Eun-Jin Go, Jung Sun Yum
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-06-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/6/e004799.full

Similar Items

Comparative network-based analysis of toll-like receptor agonist, L-pampo signaling pathways in immune and cancer cells
by: Sera Park, et al.
Published: (2024-07-01)

Intratumoral delivery of mRNA encoding the endogenous TLR2/6 agonist UNE-C1 induces immunogenic cell death and enhances antitumor activity
by: Uijoo Kim, et al.
Published: (2024-11-01)

COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity
by: Soo-Kyung Jeong, et al.
Published: (2021-08-01)

Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle
by: Se Jin Oh, et al.
Published: (2022-03-01)

Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
by: Won Suk Lee, et al.
Published: (2020-09-01)

Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade
by: Francois Xavier Rwandamuriye, et al.
Published: (2024-12-01)

Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy
by: Donghwan Jeon, et al.
Published: (2024-05-01)

The impact of intratumor heterogeneity on anti-tumor immunity
by: Nguyen, Kim Bich
Published: (2023)

Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors
by: Mario M Soldevilla, et al.
Published: (2018-08-01)

Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer
by: Won Suk Lee, et al.
Published: (2024-10-01)

Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy
by: Keunok Jung, et al.
Published: (2022-10-01)

Regulatory T cells in immune checkpoint blockade antitumor therapy
by: An Zhang, et al.
Published: (2024-11-01)

Toll-like receptor 4 (TLR4): new insight immune and aging
by: Hyo-Jin Kim, et al.
Published: (2023-11-01)

Pathogen-like Nanoassemblies of Covalently Linked TLR Agonists Enhance CD8 and NK Cell-Mediated Antitumor Immunity
by: Saikat Manna, et al.
Published: (2020-10-01)

Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
by: Paola Cappello, et al.
Published: (2021-09-01)

DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects
by: Yosuke Ota, et al.
Published: (2023-01-01)

Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors
by: Baharak Bahmani, et al.
Published: (2021-03-01)

TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity
by: Shuting Wu, et al.
Published: (2025-01-01)

In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
by: In-San Kim, et al.
Published: (2021-01-01)

PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis
by: Eun-Jin Go, et al.
Published: (2023-12-01)

Yersiniose em Trachinotus marginatus (pampo): diagnóstico histopatológico e imuno-histoquímico
by: L. Romano, et al.
Published: (2012-08-01)

A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment
by: A. Farias, et al.
Published: (2021-07-01)

Blood monocyte-derived CD169+ macrophages contribute to antitumor immunity against glioblastoma
by: Hyun-Jin Kim, et al.
Published: (2022-10-01)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
by: Alice L. Hung, et al.
Published: (2018-08-01)

SIRPα blockade improves the antitumor immunity of radiotherapy in colorectal cancer
by: Kai Ji, et al.
Published: (2023-06-01)

Insights into the Effect of Catalytic Intratumoral Lactate Depletion on Metabolic Reprogramming and Immune Activation for Antitumoral Activity
by: Junlong Zhao, et al.
Published: (2023-02-01)

Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
by: Junghwa Lee, et al.
Published: (2023-07-01)

Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction
by: Luis Alejandro Zúñiga, et al.
Published: (2022-09-01)

Immune checkpoint blockade therapy for bladder cancer treatment
by: Jayoung Kim
Published: (2016-06-01)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
by: Xiao Yang, et al.
Published: (2022-01-01)

304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma
by: Kim Margolin, et al.
Published: (2020-11-01)

TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
by: Caleb Gonzalez, et al.
Published: (2023-01-01)

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
by: Caterina Cascini, et al.
Published: (2023-06-01)

Modulation of Innate Immune Responses via Covalently Linked TLR Agonists
by: Janine K. Tom, et al.
Published: (2015-10-01)

In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade
by: Veronique Beiss, et al.
Published: (2022-12-01)

Photothermally sensitive gold nanocage augments the antitumor efficiency of immune checkpoint blockade in immune “cold” tumors
by: Guixiu Xiao, et al.
Published: (2023-10-01)

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
by: Ahmed I. Younes, et al.
Published: (2021-02-01)

Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis
by: Ha-Ram Park, et al.
Published: (2022-07-01)

Durable antitumor responses to CD47 blockade require adaptive immune stimulation
by: Sockolosky, Jonathan T., et al.
Published: (2016)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
by: Xia Liu, et al.
Published: (2022-10-01)